Clinical bottom line
Anti-CD47 therapies represent a promising, yet still investigational, approach for treatment-resistant lupus nephritis (LN), particularly in patients who have failed conventional immunosuppressive regimens. By targeting the CD47 “don’t eat me” signal on pathogenic immune cells, these agents aim to enhance phagocytic clearance and modulate immune dysregulation implicated in LN pathogenesis. Early preclinical and emerging clinical data suggest potential benefits in reducing renal inflammation and improving histologic outcomes. However, robust clinical trial evidence is currently lacking, and safety, optimal patient selection, and long-term efficacy remain to be established. Thus, anti-CD47 therapies should be considered putative and warrant further validation before routine clinical use.
What the evidence shows
Lupus nephritis remains a major cause of morbidity and mortality in systemic lupus erythematosus (SLE), with a subset of patients exhibiting resistance to standard therapies such as corticosteroids, mycophenolate mofetil, and rituximab (Lee et al., 2026; Davies et al., 2013). The unmet need for novel therapies has driven exploration of immune checkpoint pathways, including CD47, a transmembrane protein that inhibits phagocytosis by binding signal regulatory protein alpha (SIRPα) on macrophages.
Preclinical models of LN have demonstrated that blockade of CD47 can promote clearance of autoreactive immune cells and apoptotic debris, potentially reducing immune complex deposition and renal inflammation (Lee et al., 2026). This mechanism is hypothesized to restore immune homeostasis and attenuate glomerular injury. Early-phase clinical trials in other autoimmune and oncologic contexts have reported manageable safety profiles for anti-CD47 monoclonal antibodies, supporting feasibility for LN application.
Although no large randomized controlled trials have yet reported definitive efficacy data for anti-CD47 therapies in LN, recent reviews highlight their potential as adjunctive agents in refractory cases where conventional immunosuppression fails (Lee et al., 2026; Radhakrishnan et al., 2016). These therapies may complement existing regimens by targeting distinct pathogenic pathways not addressed by B-cell depletion or anti-inflammatory agents.
Caveats and uncertainty
The current evidence base for anti-CD47 therapies in LN is preliminary and largely hypothesis-generating. Most data derive from animal models or extrapolation from other disease states, with limited direct clinical experience in LN patients. The heterogeneity of LN phenotypes and variable responses to immunomodulation complicate assessment of therapeutic benefit.
Safety concerns include potential off-target effects such as anemia or thrombocytopenia due to CD47 expression on erythrocytes and platelets, necessitating careful monitoring. Long-term immunologic consequences and risk of infection remain unknown. Furthermore, optimal dosing, timing relative to standard therapies, and patient populations most likely to benefit have not been defined.
Given these uncertainties, anti-CD47 therapies should not replace established treatments such as mycophenolate mofetil or corticosteroids but may be considered investigational options within clinical trials or specialized centers (Chan et al., 2010; Lee et al., 2026).
How this may change practice
If ongoing and future studies confirm efficacy and safety, anti-CD47 therapies could expand the therapeutic arsenal for treatment-resistant LN, offering a novel mechanism to overcome refractory disease. This would be particularly valuable for patients with proliferative LN subtypes who fail current immunosuppressive regimens, a group with poor prognosis and limited options (Lee et al., 2026; Glassock et al., 2010).
Clinicians should remain informed about emerging trial results and consider referral of eligible patients to clinical studies evaluating anti-CD47 agents. Integration of these therapies into practice will require multidisciplinary collaboration, including nephrologists, rheumatologists, and immunologists, to optimize patient selection and monitoring.
Until more definitive data are available, anti-CD47 therapies remain investigational and should be used cautiously, prioritizing evidence-based standard-of-care treatments and guideline recommendations (Lee et al., 2026).